JAK2V617F somatic mutation in the general population: Myeloproliferative neoplasm development and progression rate

Haematologica

Volumn 99, Issue 9, 2014, Pages 1448-1455

  Nielsen, Camilla ^a,b   Bojesen, Stig E ^a,b   Nordestgaard, Børge G ^a,b   Kofoed, Klaus F ^a,c   Birgens, Henrik S ^a,b  

^a Department of Clinical Biochemistry Herlev Hospital Copenhagen University Hospital ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; LACTATE DEHYDROGENASE; EPO PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CONTROLLED STUDY; DISEASE SEVERITY; DNA ISOLATION; ERYTHROCYTE VOLUME FRACTION; FEMALE; FLOW CYTOMETER; GENE; GENOTYPE; HEMATOLOGICAL PARAMETERS; HUMAN; IMAGING; JAK2V617F GENE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; ORGAN SIZE; POLYCYTHEMIA VERA; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; SOMATIC MUTATION; SPLEEN IMAGING; SPLENIC VOLUME; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; VERY ELDERLY; DENMARK; DISEASE COURSE; GENETIC SCREENING; GENETICS; HEMATOLOGIC NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; PROSPECTIVE STUDY; REGISTER; SEVERITY OF ILLNESS INDEX; THROMBOCYTE;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; DENMARK; DISEASE PROGRESSION; ERYTHROCYTE INDICES; ERYTHROPOIETIN; FEMALE; GENETIC TESTING; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PLATELET COUNT; PROSPECTIVE STUDIES; REGISTRIES; SEVERITY OF ILLNESS INDEX;

EID: 84907358201     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.107631     Document Type: Article

References (20)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
2. de Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloprolifera-tive disorders. J Thromb Haemost. 2007; 5(4):708-714.
3. Sidon P, El Housni H, Dessars B, Heimann P. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia. 2006; 20(9):1622.
4. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, et al. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 2007; 109(1):339-342.
5. Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011;96(3):450-453.
6. Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE. Diagnostic value of JAK2 V617F somatic mutation for myeloprolifer-ative cancer in 49 488 individuals from the general population. Br J Haematol. 2013; 160(1):70-79.
7. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945-1953.
8. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofi-brosis--impact on disease phenotype. Eur J Haematol. 2007;79(6):508-515.
9. Vannucchi AM, Pieri L, Guglielmelli P. JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. Ther Adv Hematol. 2011;2(1):21-32.
10. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008; 299(21):2524-2532.
11. Nordestgaard BG, Benn M, Schnohr P, and Tybjaerg-Hansen A. Nonfasting triglyc-erides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308.
12. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897-1908.
13. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009; 41(4):446-449.
14. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-459.
15. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-454.
16. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53(4): 441-449.
17. Theocharides A, Passweg JR, Medinger M, Looser R, Li S, Hao-Shen H, et al. The allele burden of JAK2 mutations remains stable over several years in patients with myelo-proliferative disorders. Haematologica. 2008;93(12):1890-1893.
18. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofi-brosis--impact on disease phenotype. Eur J Haematol. 2007;79(6):508-515.
19. Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial/ethnic factors associated with myeloprolifera-tive neoplasms. Am J Hematol. 2012;87 (2):175-182.
20. Pagliarini-e-Silva S, Santos BC, Pereira EM, Ferreira ME, Baraldi EC, Sell AM, et al. Evaluation of the association between the JAK2 46/1 haplotype and chronic myelo-proliferative neoplasms in a Brazilian population. Clinics (Sao Paulo). 2013;68(1):5-9.